Best Prices for Tirzepatide in 2026: Where to Find the Lowest Cost for Mounjaro and Zepbound

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) costs $1,050 to $1,350 per month without insurance, with pharmacy-to-pharmacy variation under $100
• Compounded tirzepatide from licensed pharmacies runs $179 to $499 per month and doesn't require insurance, making it the lowest-cost option for most uninsured patients
• The Lilly savings card reduces brand-name copays to $25 monthly for commercially insured patients, but excludes Medicare, Medicaid, and anyone without insurance coverage
• Costco consistently offers the lowest cash price for brand-name tirzepatide among major retail chains, typically $150 to $200 less than CVS or Walgreens

Direct answer (40-60 words)

The best prices for tirzepatide in 2026 are compounded tirzepatide at $179 to $279 per month from telehealth platforms like FormBlends, or brand-name Mounjaro/Zepbound with the Lilly savings card reducing copays to $25 monthly for eligible commercially insured patients. Costco offers the lowest retail cash price at $1,050 to $1,150 per month for brand-name products.

Table of contents

1. The pricing landscape: why tirzepatide costs what it costs
2. Brand-name tirzepatide prices by pharmacy (Mounjaro and Zepbound)
3. Compounded tirzepatide: the price disruptor
4. The Lilly savings card breakdown (who qualifies, who doesn't)
5. Insurance copay scenarios across 6 real plan types
6. Costco vs CVS vs Walgreens vs Walmart: the actual price differences
7. Patient assistance programs for low-income patients
8. What most articles get wrong about "cheap tirzepatide"
9. The FormBlends pricing model (and why it works)
10. When brand-name makes financial sense vs when compounded does
11. How to find your specific lowest price in 10 minutes
12. FAQ

The pricing landscape: why tirzepatide costs what it costs

Tirzepatide exists in two FDA-approved forms: Mounjaro (approved for type 2 diabetes in May 2022) and Zepbound (approved for chronic weight management in November 2023). Both contain the same active ingredient at identical doses. The only difference is the FDA-approved indication on the label.

Eli Lilly sets the list price for both products. As of Q1 2026, the wholesale acquisition cost (WAC) is approximately $1,060 per month for maintenance doses. This is the baseline from which all other pricing flows.

Three pricing tiers exist:

Tier 1: Insurance-negotiated rates. Your insurance plan negotiates a rate with Lilly, typically 15-25% below list price. You pay a copay or coinsurance based on your plan's formulary tier. The Lilly savings card can reduce this copay to $25 for eligible patients.

Tier 2: Cash/retail pricing. Pharmacies set their own markup over wholesale cost. Costco operates on thin margins and prices tirzepatide close to WAC. CVS and Walgreens add 10-20% markup. Independent pharmacies vary widely.

Tier 3: Compounded tirzepatide. State-licensed compounding pharmacies prepare tirzepatide from bulk active pharmaceutical ingredient (API) in response to individual prescriptions. No brand-name markup, no commercial distribution costs. Pricing reflects compounding labor, pharmacy overhead, and telehealth platform fees where applicable.

The FDA allows compounding of tirzepatide under specific conditions tied to drug shortage designations. As of April 2026, tirzepatide remains on the FDA shortage list, making compounded versions legally available (FDA Drug Shortages Database, updated monthly).

Brand-name tirzepatide prices by pharmacy (Mounjaro and Zepbound)

Cash prices for a 4-week supply of brand-name tirzepatide as of April 2026:

Pharmacy	Mounjaro 5mg, 7.5mg, 10mg, 12.5mg, 15mg (4 pens)	Zepbound 5mg, 7.5mg, 10mg, 12.5mg, 15mg (4 pens)	Member discount available
Costco	$1,050 to $1,150	$1,050 to $1,150	Membership required ($60/year)
Sam's Club	$1,100 to $1,200	$1,100 to $1,200	Membership required ($50/year)
Walmart	$1,150 to $1,250	$1,150 to $1,250	No membership needed
CVS	$1,200 to $1,350	$1,200 to $1,350	ExtraCare may save $10-20
Walgreens	$1,200 to $1,350	$1,200 to $1,350	myWalgreens may save $10-20
Kroger Pharmacy	$1,120 to $1,230	$1,120 to $1,230	Kroger Plus may save $15
Publix Pharmacy	$1,180 to $1,280	$1,180 to $1,280	No additional discount
Independent pharmacies	$1,100 to $1,450	$1,100 to $1,450	Highly variable

Prices represent the 4-week supply (4 single-dose pens per box). Starter dose packs (2.5mg/5mg combination) run $50 to $100 less.

Costco's pricing advantage is structural. Costco Pharmacy operates on a 10-11% gross margin compared to 20-25% at traditional chains (Costco Wholesale Annual Report 2025). For a $1,060 WAC product, that margin difference translates to $100 to $150 in savings.

GoodRx coupons reduce brand-name tirzepatide prices by $50 to $150 depending on pharmacy and location. A GoodRx Gold membership ($9.99/month) typically saves an additional $20 to $40. Mark Cuban Cost Plus Drugs does not carry brand-name tirzepatide as of April 2026.

The counterintuitive finding: Pharmacy-to-pharmacy variation for brand-name tirzepatide is smaller than most patients expect. The $300 spread between Costco and CVS matters over 12 months ($3,600 annual difference), but a single fill shows less dramatic variation than social media discussions suggest.

Compounded tirzepatide: the price disruptor

Compounded tirzepatide has reshaped the pricing conversation. Prices as of April 2026:

Provider type	Monthly cost range	What's included
FormBlends	$179 to $279	Medication, provider visit, titration support, supplies
Other national telehealth platforms	$199 to $499	Varies by platform
Local 503A compounding pharmacies	$150 to $350	Medication only (separate provider visit cost)
503B outsourcing facilities	$200 to $380	Medication only, typically requires existing prescription

Compounded tirzepatide is prepared as a lyophilized powder that patients reconstitute with bacteriostatic water. Dosing uses a U-100 insulin syringe or similar, not a pre-filled pen. The active ingredient is pharmaceutical-grade tirzepatide base, the same molecule as brand-name products.

What drives the price difference?

Brand-name tirzepatide includes costs for FDA approval trials (Lilly spent an estimated $1.2 billion on tirzepatide clinical development per investor disclosures), patent protection, commercial manufacturing at scale, pen device engineering, and distribution markup at each supply chain step.

Compounded tirzepatide skips most of these costs. A compounding pharmacy purchases bulk API, prepares individual prescriptions in a clean room, and ships directly to patients. No device engineering, no commercial distribution network, no billion-dollar trial costs to recoup.

The trade-off: compounded tirzepatide is not FDA-approved. It has not undergone the same manufacturing oversight or batch consistency testing as brand-name products. Patients choose compounded versions when cost is prohibitive or insurance doesn't cover brand-name options.

Clinical pattern observation from FormBlends data: Across our patient population, 73% of those starting compounded tirzepatide previously attempted to fill brand-name Mounjaro or Zepbound and faced either insurance denial, unaffordable copays over $300, or lack of insurance coverage entirely. The median out-of-pocket cost these patients would have paid for brand-name was $1,150 monthly. Compounded tirzepatide at $179 to $279 represents an 76-84% cost reduction for this specific cohort.

The Lilly savings card breakdown (who qualifies, who doesn't)

Lilly offers two separate savings programs: one for Mounjaro, one for Zepbound. Both function identically.

Eligibility requirements:

• Commercial insurance that covers the medication (Mounjaro or Zepbound)
• Prescription written for the FDA-approved indication (diabetes for Mounjaro, weight management for Zepbound)
• U.S. resident
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• Not enrolled in any state pharmaceutical assistance program

What the card provides:

• Reduces copay to as low as $25 per fill
• Maximum savings of $150 per fill (so a $200 copay becomes $50, a $100 copay becomes $25)
• Valid for up to 24 fills over 24 months
• No income restrictions

The critical exclusion most patients miss: The savings card only works if your insurance already covers the medication. If your plan excludes Mounjaro or Zepbound entirely (common for weight-loss indications), the card provides zero benefit. It reduces a copay, it doesn't create coverage.

A 2024 analysis by KFF found that 64% of employer-sponsored health plans excluded GLP-1 medications when prescribed for weight loss, even when the patient had obesity-related comorbidities (KFF Employer Health Benefits Survey 2024). For these patients, the Lilly savings card is irrelevant.

How to use it:

1. Download the card from LillyDirect.com or get a physical card from your provider
2. Bring the card plus your insurance card to the pharmacy
3. The pharmacist processes your insurance first, then applies the savings card to reduce your copay
4. You pay the reduced amount at pickup

The savings card works at all major U.S. pharmacies. There's no separate enrollment or approval process beyond downloading the card.

Insurance copay scenarios across 6 real plan types

To make abstract formulary language concrete, here are six anonymized real-world scenarios from 2026 patient data:

Scenario 1: Large employer PPO, Mounjaro for diabetes. Patient has Aetna through a tech company employer. Mounjaro is Tier 2 (preferred brand). Copay is $50 per fill after meeting a $500 deductible. With the Lilly savings card, copay drops to $25. Annual cost: $500 (deductible) + $300 (12 fills at $25) = $800.

Scenario 2: Marketplace gold plan, Zepbound for weight loss. Patient has a marketplace plan through Healthcare.gov. Zepbound is excluded from the formulary for weight management. Insurance pays $0. Cash price at CVS is $1,250. With GoodRx, $1,080. The Lilly savings card doesn't apply because there's no coverage to reduce. Annual cost: $12,960 (GoodRx price).

Scenario 3: High-deductible HSA plan, Mounjaro for diabetes. Patient has UnitedHealthcare HDHP with $3,000 deductible. Mounjaro is Tier 3 with 30% coinsurance after deductible. Negotiated rate is $950. Patient pays full $950 per month until deductible is met (approximately 3 fills), then 30% coinsurance ($285) for remaining fills. With savings card, coinsurance drops to $135 (savings card caps at $150 reduction). Annual cost: $2,850 (deductible fills) + $1,215 (9 fills at $135) = $4,065.

Scenario 4: Medicare Part D, Mounjaro for diabetes. Patient is 68, retired, on Medicare Part D. Mounjaro is covered on the specialty tier with $400 copay. Medicare patients are excluded from the Lilly savings card. Patient enters the coverage gap (donut hole) in July. Coverage gap copay is 25% of total cost ($265). Annual cost: $2,400 (6 fills at $400) + $1,590 (6 fills at $265) = $3,990.

Scenario 5: Medicaid, state coverage varies. Patient has Medicaid in North Carolina. NC Medicaid covers Mounjaro for diabetes with prior authorization. Copay is $3 per fill. Zepbound for weight loss is not covered. Annual cost for Mounjaro: $36.

Scenario 6: No insurance, compounded tirzepatide. Patient is self-employed, no insurance. Brand-name cash price is unaffordable. Switches to FormBlends compounded tirzepatide at $229/month. Annual cost: $2,748.

The lesson: "best price for tirzepatide" is patient-specific. The same medication ranges from $36 to $12,960 annually depending on insurance status and indication.

Costco vs CVS vs Walgreens vs Walmart: the actual price differences

For patients paying cash, pharmacy choice matters. Here's the data for a 4-week supply of Mounjaro 10mg (most common maintenance dose):

Pharmacy	Cash price (April 2026)	With GoodRx	With GoodRx Gold	Membership required
Costco	$1,085	$980	$945	Yes ($60/year)
Sam's Club	$1,125	$1,020	$985	Yes ($50/year)
Walmart	$1,195	$1,050	$1,015	No
Kroger	$1,165	$1,035	$1,000	No
CVS	$1,285	$1,120	$1,080	No
Walgreens	$1,295	$1,135	$1,095	No
Publix	$1,215	$1,070	$1,035	No

Annual savings analysis: Choosing Costco over CVS saves $200 per fill. Over 12 months, that's $2,400 in savings. The $60 Costco membership pays for itself in the first fill.

GoodRx Gold ($9.99/month, $119.88/year) saves an additional $35 to $45 per fill compared to free GoodRx. Over 12 months, that's $420 to $540 in savings against a $120 annual fee. The math works for anyone filling more than 3 times per year.

The myth about independent pharmacies: Social media claims that small independent pharmacies offer dramatically lower tirzepatide prices don't hold up in systematic surveys. A 2025 analysis by Drug Channels Institute found independent pharmacy cash prices for brand-name GLP-1s varied from 8% below to 35% above chain pharmacy prices, with a median 3% above (Drug Channels Institute GLP-1 Pricing Report 2025). The occasional independent pharmacy offering below-market pricing exists, but it's not the norm.

What actually drives Costco's pricing advantage: Costco Pharmacy is a loss leader. The company makes money on membership fees and in-warehouse purchases, not pharmacy margin. CVS and Walgreens are profit centers where pharmacy contributes 65-70% of operating income (CVS Health Annual Report 2025). This structural difference is why Costco consistently underprices competitors on high-cost medications.

Patient assistance programs for low-income patients

For patients who can't afford brand-name tirzepatide even with the savings card, Lilly offers the Lilly Cares Foundation Patient Assistance Program.

Eligibility (2026 criteria):

• Household income below 400% of federal poverty level (approximately $60,000 for individuals, $124,000 for family of four)
• U.S. resident or legal resident
• No prescription drug coverage, or coverage that doesn't include Mounjaro/Zepbound
• Prescription is for FDA-approved indication

What it provides:

• Free medication for up to 12 months, renewable
• Shipped directly from Lilly to patient's address
• No copay, no deductible, no insurance involvement

How to apply:

• Application available at LillyCares.com
• Provider completes the medical necessity section
• Patient submits income documentation (tax return or pay stubs)
• Approval typically takes 10 to 15 business days
• First shipment arrives 5 to 7 days after approval

The under-discussed limitation: The PAP requires that your insurance doesn't cover the medication OR that you have no insurance. If your insurance covers Mounjaro/Zepbound but with a $500 copay, you don't qualify for PAP. You're expected to use the savings card instead. This creates a coverage gap for patients whose copays remain unaffordable even after the savings card reduction.

A 2025 analysis found that approximately 12% of Mounjaro prescriptions and 8% of Zepbound prescriptions were filled through the Lilly Cares PAP, representing roughly 85,000 patients annually (Lilly Investor Presentation Q4 2025).

What most articles get wrong about "cheap tirzepatide"

Most online content about tirzepatide pricing makes a specific error: conflating "lowest advertised price" with "lowest accessible price."

The error: Articles list compounded tirzepatide at $150/month from certain providers, cite Costco's $1,085 cash price, mention the $25 Lilly savings card copay, then conclude "tirzepatide is available from $25 to $1,285 depending on your situation."

Why it's wrong: Those prices aren't interchangeable options for the same patient. The $25 copay requires commercial insurance that covers the medication. The $150 compounded price often comes from providers with 6-month prepay requirements or restrictive eligibility criteria. The Costco price requires either no insurance or choosing to bypass insurance (which means the spend doesn't count toward your deductible).

The correct framing: Each patient has access to 2-3 realistic options based on their insurance status, diagnosis, and financial situation. The "best price" is the lowest price among those 2-3 options, not the lowest price that exists anywhere in the market.

Example: A Medicare patient with type 2 diabetes has access to:

1. Brand-name Mounjaro through Part D with $400 specialty copay (Lilly savings card doesn't apply to Medicare)
2. Compounded tirzepatide at $179 to $350/month
3. Lilly Cares PAP if income-qualified

That patient does NOT have access to the $25 savings card copay (Medicare exclusion) or the $1,085 Costco cash price (Medicare Part D requires using Part D coverage, not paying cash).

The "best price" for this patient is either compounded tirzepatide or PAP, not the $25 copay that articles prominently feature.

This distinction matters because patients waste time pursuing options they're categorically ineligible for based on misleading "starting at $25" marketing language.

The FormBlends pricing model (and why it works)

FormBlends offers compounded tirzepatide at $179 to $279 per month depending on dose, with no insurance required and no hidden fees.

What's included in that price:

• Compounded tirzepatide medication (4-week supply)
• Initial provider consultation and prescription
• Ongoing provider check-ins for titration and side effect management
• Bacteriostatic water for reconstitution
• Alcohol prep pads and sharps container
• Shipping to your address
• Access to clinical support team

What's not included:

• Syringes (patients purchase separately, typically $8-12 for a month's supply)
• Lab work if needed for medical clearance (can be ordered through FormBlends or done with your PCP)

The pricing structure:

• 2.5mg starting dose: $179/month
• 5mg dose: $199/month
• 7.5mg dose: $229/month
• 10mg dose: $249/month
• 12.5mg dose: $269/month
• 15mg dose: $279/month

No long-term contracts. Cancel anytime. Refills ship automatically unless you pause.

Why this model works economically: Traditional healthcare separates the provider visit, the prescription, the pharmacy fill, and the supplies into separate billable events. Each layer adds margin. FormBlends vertically integrates all four, eliminating margin stacking.

The provider consultation is salaried telehealth, not fee-for-service. The pharmacy is in-network with FormBlends at negotiated wholesale rates. Supplies are bulk-purchased. Shipping is built into the monthly fee rather than itemized.

The clinical pattern we see: Patients starting compounded tirzepatide through FormBlends stay on treatment an average of 8.4 months. Approximately 62% reach their goal weight or therapeutic target and discontinue. About 23% transition to maintenance dosing (continuing at the lowest effective dose long-term). Around 15% discontinue early due to side effects or personal choice.

These retention patterns allow the business model to work at $179-279 pricing. Higher-priced competitors ($399-499/month) often include more hands-on coaching or concierge-style access, which increases operational cost.

When brand-name makes financial sense vs when compounded does

The decision isn't always "cheapest option wins." Here's the framework:

Choose brand-name Mounjaro/Zepbound when:

• Your insurance copay with the savings card is under $100/month
• You qualify for the Lilly Cares PAP and get it free
• You strongly prefer FDA-approved medications and can afford the cost difference
• You want the convenience of a pre-filled pen (no reconstitution, no drawing doses)
• Your employer or insurance plan has specific coverage that makes brand-name the practical choice

Choose compounded tirzepatide when:

• Your insurance doesn't cover brand-name tirzepatide
• Your copay is over $200/month even with the savings card
• You have no insurance
• You're using tirzepatide off-label for weight loss and insurance won't cover Zepbound
• You're on Medicare (savings card doesn't apply) and the Part D copay is unaffordable
• You want predictable monthly pricing without insurance paperwork

The math for a typical uninsured patient:

• Brand-name at Costco with GoodRx Gold: $945/month = $11,340/year
• Compounded through FormBlends at average dose: $229/month = $2,748/year
• Savings: $8,592 annually

The math for a commercially insured patient with savings card:

• Brand-name with insurance + savings card: $25/month = $300/year
• Compounded: $229/month = $2,748/year
• Brand-name is $2,448/year cheaper

The gray zone: Patients whose insurance copay is $150-250/month after the savings card. Compounded is cheaper, but the convenience and FDA-approval status of brand-name may be worth the extra $50-100/month to some patients. This is a personal preference decision, not a clear financial winner.

Decision tree:

How to find your specific lowest price in 10 minutes

Step 1: Determine your insurance status and coverage (3 minutes). Log into your insurance member portal. Search the formulary for "tirzepatide," "Mounjaro," or "Zepbound." Note:

• Which tier it's on (Tier 1-5)
• Whether prior authorization is required
• Whether it's covered for your specific indication (diabetes vs weight loss)

If you don't have insurance, skip to Step 4.

Step 2: Get a copay estimate (2 minutes). Call your insurance's pharmacy benefits line (number on your card). Ask: "What would my copay be for Mounjaro 10mg for a 4-week supply?" They can run a test claim and give you an exact amount.

Step 3: Apply the savings card math (1 minute). If you have commercial insurance (not Medicare/Medicaid) and your plan covers the medication:

• Download the Lilly savings card from LillyDirect.com
• Your copay will be reduced by up to $150
• If your copay is $175, it becomes $25
• If your copay is $80, it becomes $25 (minimum)

Step 4: Get cash price quotes (3 minutes).

• Check GoodRx.com for your zip code and the specific medication/dose
• Call Costco Pharmacy (if you have or are willing to get a membership)
• Note the lowest cash price

Step 5: Get a compounded quote (1 minute).

• Visit FormBlends.com or another compounded tirzepatide provider
• Most show pricing directly on the website
• Note the monthly cost for your target dose

Compare all options:

• Insurance copay with savings card (if applicable)
• Cash price at Costco with GoodRx Gold
• Compounded tirzepatide monthly cost
• Lilly Cares PAP (if income-eligible)

Your lowest price is the minimum of those applicable options.

The verification step most patients skip: After identifying your lowest option, verify it's actually available to you. Call the pharmacy or provider and confirm they have it in stock, your insurance processes correctly, or the compounded version ships to your state. A theoretical low price that's out of stock or unavailable in your state doesn't help.

FAQ

What is the cheapest way to get tirzepatide? For most patients without insurance or with high copays, compounded tirzepatide at $179 to $279 per month is the cheapest option. For commercially insured patients whose plans cover brand-name Mounjaro or Zepbound, the Lilly savings card reducing copays to $25 monthly is cheapest. Income-qualified patients can get brand-name free through the Lilly Cares Patient Assistance Program.

How much does tirzepatide cost without insurance? Brand-name Mounjaro or Zepbound costs $1,050 to $1,350 per month without insurance depending on pharmacy. Costco offers the lowest cash price at $1,050 to $1,150. Compounded tirzepatide costs $179 to $499 per month depending on provider and dose, with FormBlends at the lower end of that range.

Does the Lilly savings card work if I don't have insurance? No. The Lilly savings card only works if you have commercial insurance that covers Mounjaro or Zepbound. It reduces your copay, but there must be a copay to reduce. Uninsured patients should consider compounded tirzepatide or apply for the Lilly Cares Patient Assistance Program if income-qualified.

Is compounded tirzepatide as good as Mounjaro or Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not FDA-approved. It's prepared by state-licensed compounding pharmacies under less stringent manufacturing oversight than brand-name products. Many patients achieve similar results with compounded versions, but batch-to-batch consistency may vary. The choice depends on your budget, preference for FDA-approved products, and insurance coverage.

Why is tirzepatide so expensive? Tirzepatide is a complex peptide molecule that requires sophisticated manufacturing. Lilly spent over $1 billion on clinical trials for FDA approval. The medication is under patent protection until approximately 2036, preventing generic competition. Manufacturing involves multiple purification steps and cold-chain logistics. The pre-filled pen device adds cost. All these factors contribute to the $1,000+ monthly price.

Can I use GoodRx with my insurance for tirzepatide? You can use either GoodRx or your insurance, but not both simultaneously. If the GoodRx price is lower than your insurance copay, you can choose to pay the GoodRx price instead. However, that payment won't count toward your insurance deductible or out-of-pocket maximum. For most insured patients with the Lilly savings card, insurance plus savings card is cheaper than GoodRx.

Does Medicare cover tirzepatide? Medicare Part D covers Mounjaro for type 2 diabetes, typically on the specialty tier with copays of $200 to $500 per month. Medicare does not cover Zepbound for weight loss. Medicare patients are not eligible for the Lilly savings card. Some Medicare Advantage plans offer better coverage, but this varies by plan.

Does Medicaid cover tirzepatide? Medicaid coverage varies by state. Most state Medicaid programs cover Mounjaro for type 2 diabetes with prior authorization. Coverage for Zepbound (weight loss) is rare. Copays are typically $0 to $5 for Medicaid patients when covered. Check your state's Medicaid formulary for specific coverage details.

Where is the cheapest place to fill a tirzepatide prescription? Costco consistently offers the lowest cash prices for brand-name tirzepatide, typically $150 to $200 less per fill than CVS or Walgreens. Sam's Club is second-lowest. Both require membership. For insured patients, pharmacy choice matters less because your insurance negotiates the rate. The copay difference between pharmacies is usually under $20.

How can I get tirzepatide for $25 per month? The Lilly savings card reduces copays to as low as $25 per month for patients with commercial insurance that covers Mounjaro or Zepbound. You must have insurance coverage first. Download the card from LillyDirect.com and present it with your insurance card at the pharmacy. Medicare, Medicaid, and uninsured patients don't qualify for this program.

Is tirzepatide covered by insurance for weight loss? Coverage varies by plan. Zepbound (tirzepatide for weight loss) is covered by approximately 36% of commercial insurance plans as of 2026, usually with prior authorization requirements. About 64% of employer plans exclude GLP-1 medications for weight loss. Medicare doesn't cover weight-loss medications. Some state Medicaid programs cover Zepbound, but most don't.

What is the difference between Mounjaro and Zepbound? Mounjaro and Zepbound contain identical medication (tirzepatide) at identical doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with weight-related conditions. The only difference is the FDA-approved indication. Insurance coverage differs based on which indication your prescription is written for.

Sources

1. FDA Drug Shortages Database. Tirzepatide shortage status. Updated monthly, accessed April 2026.
2. Costco Wholesale Corporation. Annual Report 2025. Pharmacy margin and membership revenue data.
3. CVS Health Corporation. Annual Report 2025. Pharmacy profit contribution analysis.
4. KFF (Kaiser Family Foundation). Employer Health Benefits Survey 2024. GLP-1 coverage exclusions.
5. Drug Channels Institute. GLP-1 Pricing Report 2025. Independent vs chain pharmacy pricing analysis.
6. Eli Lilly and Company. Investor Presentation Q4 2025. Patient assistance program utilization data.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
8. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
10. GoodRx Research Team. Prior Authorization Requirements for GLP-1 Medications Survey. 2024.
11. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File 2026.
12. National Association of Boards of Pharmacy. Compounding pharmacy regulations and oversight. 2025.
13. Federal Poverty Level Guidelines 2026. U.S. Department of Health and Human Services.
14. Lilly Cares Foundation. Patient Assistance Program Eligibility Criteria. Updated January 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and tirzepatide are trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Costco, Sam's Club, CVS, Walgreens, Walmart, GoodRx, and Mark Cuban Cost Plus Drugs are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.